Close Menu

NEW YORK (360Dx) – Startup Octave Bioscience has closed a $14 million Series A round of financing, which will fund the firm's efforts to develop a platform for the management of patients with multiple sclerosis.

Launched two years ago by William Hagstrom, formerly the CEO of rheumatoid arthritis testing firm Crescendo Bioscience, Octave aims to integrate protein biomarker measurements, data from patient wearables, and imaging to improve management of MS.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.